Skip to main content

Advertisement

SpringerLink
Log in

Effect of the women’s health initiative on prescription anti-osteoporosis medication utilization

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Publication of the Women’s Health Initiative (WHI) resulted in a 39% reduction in hormone therapy utilization and a 29% increase in the use of new anti-osteoporosis medications. Overall, the prevalence of prescription anti-osteoporosis medication use declined following the WHI. This has important implications for osteoporosis prevention and treatment.

Introduction

Women who discontinued hormone therapy (HT) following the Women’s Health Initiative (WHI) may have been more likely to initiate treatment with newer anti-osteoporosis medications (AOM). The objective of this study was to examine the influence of the WHI on AOM utilization among a nationally representative sample of older adult women in the U.S.

Methods

We used the Medical Expenditure Panel Survey (MEPS) to examine AOM utilization among women aged 50 years and older. National estimates of AOM utilization were predicted from a sample of 2089 women interviewed five times between 2002 and 2003. AOM utilization was dichotomized for HT and newer AOM. Generalized estimating equations were used to predict odds ratios (OR) for AOM utilization controlling for potential predisposing, enabling, and need confounders.

Results

Prior to the WHI, there were 8.7 and 3.6 million U.S. women using HT and newer AOM, respectively. One year following publication of the WHI, 5.3 million HT users persisted [OR 0.638 (95% CI: 0.617, 0.756)] while 4.7 million women used newer AOM [1.337 (95% CI: 1.120, 1.597)].

Conclusions

Although reductions in HT utilization were accompanied by increased utilization of newer AOM, treatment prevalence for osteoporosis remains sub-optimal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barrett-Connor E, Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Rev Public Health 19:55–72

    Article  CAS  Google Scholar 

  2. Writing group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  Google Scholar 

  3. Rossouw JE, Prentice RL, Manson JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465–1477

    Article  CAS  PubMed  Google Scholar 

  4. The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA 291:1701–1712

    Article  Google Scholar 

  5. Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738

    Article  CAS  PubMed  Google Scholar 

  6. Yates J, Barrett-Connor E, Barlas S et al (2004) Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 103:440–446

    Article  CAS  PubMed  Google Scholar 

  7. Boonen S, Body JJ, Boutsen Y et al (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239–254

    Article  PubMed  Google Scholar 

  8. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53

    Article  CAS  PubMed  Google Scholar 

  9. Majumdar SR, Almasi EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 292:1983–1988

    Article  CAS  PubMed  Google Scholar 

  10. Medical Expenditure Panel Survey. Accessed at: http://www.meps.ahrq.gov/mepsweb/data_stats/download_data_files.jsp on 5 August 2007

  11. Cohen SB (2003) Design strategies and innovations in the medical expenditure panel survey. Med Care 41(7 Suppl):III5–III12

    PubMed  Google Scholar 

  12. Andersen RM (1995) Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 36:1–10

    Article  CAS  PubMed  Google Scholar 

  13. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503

    Article  Google Scholar 

  14. Saag KG (1997) Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am J Med 103:31S–39S

    Article  CAS  PubMed  Google Scholar 

  15. Dequeker J, Westhovens R (1995) Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention. J Rheumatol 22:1013–1019

    CAS  PubMed  Google Scholar 

  16. Simon JA, Wehren LE, Ascott-Evans BH et al (2006) Skeletal consequences of hormone therapy discontinuance: a systematic review. Obstet Gynecol Surv 61:115–124

    Article  PubMed  Google Scholar 

  17. Lee E, Wutoh AK, Xue Z et al (2006) Osteoporosis management in a Medicaid population after the Women’s Health Initiative study. J Womens Health (Larchmt) 15:155–161

    Article  Google Scholar 

  18. Udell JA, Fischer MA, Brookhart MA et al (2006) Effect of the Women’s Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 21:765–771

    Article  PubMed  Google Scholar 

  19. National Osteoporosis Foundation (2002) America’s bone health: the state of osteoporosis and low bone mass in our nation. National Osteoporosis Foundation, Washington, DC

    Google Scholar 

  20. Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822

    Article  CAS  PubMed  Google Scholar 

  21. Solomon DH, Finkelstein JS, Katz JN et al (2003) Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 115:398–400

    Article  PubMed  Google Scholar 

  22. Freedman KB, Kaplan FS, Bilker WB et al (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 82-A:1063–1070

    CAS  PubMed  Google Scholar 

  23. Cuddihy MT, Gabriel SE, Crowson CS et al (2002) Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med 162:421–426

    Article  PubMed  Google Scholar 

  24. Manson JE, Allison MA, Rossouw JE et al (2007) Estrogen therapy and coronary-artery calcification. New Engl J Med 356:2591–2602

    Article  CAS  PubMed  Google Scholar 

  25. Farley JF, Cline RR, Gupta K (2006) Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). Osteoporos Int 17:395–404

    Article  PubMed  Google Scholar 

  26. Gourlay ML, Callahan LF, Preisser JS et al (2007) Osteoporosis preventive care in white and black women in community family medicine settings. South Med J 100:677–682

    Article  PubMed  Google Scholar 

  27. Mudano AS, Casebeer L, Patino F et al (2003) Racial disparities in osteoporosis prevention in a managed care population. South Med J 96:445–451

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, CB #7360, 2201 Kerr Hall, Chapel Hill, NC, 27599-7360, USA

    J. F. Farley & S. J. Blalock

  2. Department of Pharmaceutical Care and Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, MN, USA

    R. R. Cline

Authors
  1. J. F. Farley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. J. Blalock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. R. Cline
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. F. Farley.

Additional information

This study was supported by an unrestricted research grant from the American Society of Health-System Pharmacists.

Appendix

Appendix

Table 6 Full hierarchical generalized estimating equation of hormone therapy use
Full size table
Table 7 Full hierarchical generalized estimating equation of newer anti-osteoporosis medication use
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farley, J.F., Blalock, S.J. & Cline, R.R. Effect of the women’s health initiative on prescription anti-osteoporosis medication utilization. Osteoporos Int 19, 1603–1612 (2008). https://doi.org/10.1007/s00198-008-0607-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-008-0607-1

Keywords

Search

Navigation